 FOSTER CITY, Calif., Oct. 26, 2022 GLOBE NEWSWIRE -- Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis NASH, today announced that the company will present two abstracts regarding its investigational therapies TERN-501, a THR-β agonist, and TERN-101, an FXR agonist, in clinical development for the treatment of NASH at the American Association for the Study of Liver Diseases AASLD The Liver Meeting, which will be held November 4-8, 2022. The poster abstracts were published in the October 2022 supplement of Hepatology, the peer-reviewed journal of AASLD. 